Guardant Health, Inc. (GH)
Data as of Nov 3, 11:05 AM ETPrices may be delayedHow our data works
Res / Sup are automatic swing levels for educational reference only — not signals or advice.
Prices may be delayed. For informational purposes only — not investment advice.
GH key stats
GH GlowScore: Active
A 0–100 read on today's activity from volume, momentum and intraday range. Not a buy or sell signal.
About Guardant Health, Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
What's moving GH today
Updated November 3, 2026As of November 3, 2026, Guardant Health, Inc. (GH) stock climbed to $174.99, up 2.50% (+$4.26) versus the previous close. On the day, shares have traded between $167.31 and $178.38. That puts GH in the upper third of its 52-week range of $74.55 to $191.05. Guardant Health, Inc. operates in the services-medical laboratories space and carries a market capitalization of roughly $22.91 billion, with about 357.7K shares changing hands.
Latest GH news
- Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood TestYahoo Finance· Nov 3, 8:05 AM ETCRC
- What Just Happened To Natera Stock?trefis.com· Nov 3, 7:18 AM ET
- How Long Can GRAIL Keep Burning Cash?trefis.com· Nov 3, 6:56 AM ET
- Tempus AI Soars 10% on Q3 Beat and Raised Guidance as Oncology Sees “Accelerating Unit Growth”tikr.com· Nov 2, 12:00 PM ET
- CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseYahoo Finance· Nov 2, 9:00 AM ETCRSP
- Illumina Sinks 13% on Light Q3 Revenue Despite EPS Beat and Raised Guidancetikr.com· Oct 30, 10:01 AM ET
- Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseYahoo Finance· Oct 29, 9:00 AM ET
- Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for PennsylvaniansYahoo Finance· Oct 29, 8:05 AM ETACSNCCN
Source: Yahoo Finance RSS · Updated November 3, 2026
Want GH headlines, alerts and AI research in one place? Create a free account →
GH buzz on Stocktwits
5,081 watchers$GH Huge award, The Prix Galien USA is the premier American award recognizing outstanding scientific advancements and innovations in the life sciences. Often described as the biopharmaceutical equivalent of the Nobel Prize, the awards honor breakthroughs that improve human hea…
@Gator5326· Nov 3, 8:15 AM ET· Bullish
$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyf7-2BfqgDTPA1pwQgPEK0LIAuw5-2FChzwlzQzS-2FUezgn5fc-2FogGMrrGJtCRiNGV6MVK8HA-2BBfTK36fjAUloAs1iO4rO-2FMC2qH19eclpOTL…
@Gator5326· Nov 3, 8:12 AM ET· Bullish
$GH I love revisions! Can’t argue with revenues! 😎
@Gator5326· Nov 3, 7:44 AM ET· Bullish
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: $PRPO ) will be hosting its Q3-2026 shareholder update call on November 10, 2026, at 5:00 PM ET. The call will include remarks on the Company’s current core businesses, as well as a moderated live Q&A session at …
@B2iDigital· Oct 29, 1:25 PM ET
$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyf7-2BfqgDTPA1pwQgPEK0LIApNmd4Z3UMPMXe6HpgHi1SlzWMHwYUdCNRLWXGFGJDJ5k4NwDMmsD4TOxgIi04Ud946UObgFj4-2BgdQiIyHG1Q1wK2i…
@Gator5326· Oct 29, 8:44 AM ET
Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →
GH Congress & insider trades
Congress amounts are the disclosed ranges; filings can lag the trade date by up to 45 days.
AI research on GH
Get an instant AI breakdown of the bull & bear case, key risks, and what analysts are watching.
Not financial advice. This page is for educational purposes only. Data comes from third-party sources, may be delayed or incomplete, and should not be the basis of any investment decision.